Arbaclofen Placerbil was believed to have therapeutic potential in treating gastroesophogeal reflux disease (GERD) and plasticity; however due to discouraging clinical trial results, the drug was abandoned by XenoPort in 2011 for the treatment of GERD. On May 20th, 2013, XenoPort announced plans to terminate the development of Arbaclofen Placerbil for the treatment of multiple sclerosis."""@en ; dct:identifier "drugbank:DB08892" ; dct:title "Arbaclofen Placarbil"@en ; adv:Drug ; rdfs:label "Arbaclofen Placarbil [drugbank:DB08892]"@en ; rdfs:seeAlso <http://www.drugbank.ca/drugs/DB08892> . }